Cargando…

Evaluation and multi-institutional validation of a novel urine biomarker lncRNA546 to improve the diagnostic specificity of prostate cancer in PSA gray-zone

BACKGROUND AND OBJECTIVES: Prostate specific antigen (PSA) is currently the most commonly used biomarker for prostate cancer diagnosis. However, when PSA is in the gray area of 4-10 ng/ml, the diagnostic specificity of prostate cancer is extremely low, leading to overdiagnosis in many clinically fal...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Fei, Shi, Xiaolei, Wang, Fangming, Han, Sujun, Chen, Dong, Gao, Xu, Wang, Linhui, Wei, Qiang, Xing, Nianzeng, Ren, Shancheng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9411806/ https://www.ncbi.nlm.nih.gov/pubmed/36033474 http://dx.doi.org/10.3389/fonc.2022.946060

Ejemplares similares

Is PSA density of the peripheral zone as a useful predictor for prostate cancer in patients with gray zone PSA levels?
por: Lee, Jaegeun, et al.
Publicado: (2021)

Using clinical parameters to predict prostate cancer and reduce the unnecessary biopsy among patients with PSA in the gray zone
por: Liu, Junxiao, et al.
Publicado: (2020)

Preoperative red cell distribution width is associated with postoperative lymphovascular invasion in prostate cancer patients treated with radical prostatectomy: A retrospective study
por: Wang, Fangming, et al.
Publicado: (2022)

Alpha-L-Fucosidase Has Diagnostic Value in Prostate Cancer With “Gray-Zone PSA” and Inhibits Cancer Progression via Regulating Glycosylation
por: Zhang, Cong, et al.
Publicado: (2021)

Two Novel Ceramide-Like Molecules and miR-5100 Levels as Biomarkers Improve Prediction of Prostate Cancer in Gray-Zone PSA
por: Mello-Grand, Maurizia, et al.
Publicado: (2021)

Improving the detection rate of prostate cancer in the gray zone of PI-RADS v2 and serum tPSA by using prostate-specific antigen–age volume
por: Lu, Yuan-Fei, et al.
Publicado: (2019)

Diagnosis of Prostate Cancer in Patients with Prostate-Specific Antigen (PSA) in the Gray Area: Construction of 2 Predictive Models
por: Chen, Ming, et al.
Publicado: (2021)

Establishment of two new predictive models for prostate cancer to determine whether to require prostate biopsy when the PSA level is in the diagnostic gray zone (4–10 ng ml(−1))
por: Liu, Jun, et al.
Publicado: (2019)

(68)Ga-PSMA PET/CT-based multivariate model for highly accurate and noninvasive diagnosis of clinically significant prostate cancer in the PSA gray zone
por: Yang, Jinhui, et al.
Publicado: (2023)

Quercetin Inhibits Epithelial-to-Mesenchymal Transition (EMT) Process and Promotes Apoptosis in Prostate Cancer via Downregulating lncRNA MALAT1
por: Lu, Xinxing, et al.
Publicado: (2020)

Alterations in expressed prostate secretion-urine PSA N-glycosylation discriminate prostate cancer from benign prostate hyperplasia
por: Jia, Gaozhen, et al.
Publicado: (2017)

Peripheral zone PSA density: a predominant variable to improve prostate cancer detection efficiency in men with PSA higher than 4 ng ml(–1)
por: Wang, Cheng, et al.
Publicado: (2021)

Construction of a cuproptosis-associated lncRNA prognostic signature for bladder cancer and experimental validation of cuproptosis-related lncRNA UBE2Q1-AS1
por: Shen, Junlin, et al.
Publicado: (2023)

Urinary PSA and Serum PSA for Aggressive Prostate Cancer Detection
por: Höti, Naseruddin, et al.
Publicado: (2023)

The roles of miRNA, lncRNA and circRNA in the development of osteoporosis
por: Yang, Yang, et al.
Publicado: (2020)

Inclusive jet production at $\sqrt{s} = 546 GeV$
por: Arnison, Geoffrey T J, et al.
Publicado: (1985)

Hepatic copper concentrations in 546 dogs (1982–2015)
por: Strickland, Jaimie M., et al.
Publicado: (2018)

546 Health Disparities Among Rural Burn Patients
por: Duggan, Robert P, et al.
Publicado: (2022)

Diagnostic Performance of %[-2]proPSA and Prostate Health Index for Prostate Cancer: Prospective, Multi-institutional Study
por: Park, Hongzoo, et al.
Publicado: (2018)

Evaluating the Role of Morphological Parameters in the Prostate Transition Zone in PHI-Based Predictive Models for Detecting Gray Zone Prostate Cancer
por: Qian, Yu-Hang, et al.
Publicado: (2023)

Integrated Characterization of lncRNA-Immune Interactions in Prostate Cancer
por: Hu, Wei, et al.
Publicado: (2021)

Bioinformatics analysis and experimental validation of cuproptosis-related lncRNA LINC02154 in clear cell renal cell carcinoma
por: Shen, Junlin, et al.
Publicado: (2023)

Comparative risk of acute kidney injury among cancer patients treated with immune checkpoint inhibitors
por: Liu, Fei, et al.
Publicado: (2022)

Does normalizing PSA after successful treatment of chronic prostatitis with high PSA value exclude prostatic biopsy?
por: Azab, Sherif, et al.
Publicado: (2012)

A urine extracellular vesicle lncRNA classifier for high-grade prostate cancer and increased risk of progression: A multi-center study
por: Tao, Wen, et al.
Publicado: (2023)

A single mitochondrial DNA deletion accurately detects significant prostate cancer in men in the PSA ‘grey zone’
por: Creed, Jennifer, et al.
Publicado: (2017)

Detection of prostate cancer with complexed PSA and complexed/total PSA ratio - is there any advantage?
por: Strittmatter, F, et al.
Publicado: (2011)

A Novel Urine Exosomal lncRNA Assay to Improve the Detection of Prostate Cancer at Initial Biopsy: A Retrospective Multicenter Diagnostic Feasibility Study
por: Li, Yun, et al.
Publicado: (2021)

The Relationship between Prostate Biopsy Results and PSA and Free PSA Ratio Changes in Elevated Serum PSA Patients with and without Antibiotherapy
por: Duran, Mesut Berkan, et al.
Publicado: (2020)

A Comparative Performance Analysis of Total PSA, Percentage Free PSA, PSA Velocity, and PSA Density versus the Detection of Primary Circulating Prostate Cells in Predicting Initial Prostate Biopsy Findings in Chilean Men
por: Murray, Nigel P., et al.
Publicado: (2014)

Preludes and fugues BWV 544, 541, 546, 542 and 536
por: Bach, Johann Sebastian, 1685-1750
Publicado: (1992)

Association of Polymorphisms in the Prostate-Specific Antigen (PSA) Gene Promoter with Serum PSA Level and PSA Changes after Dutasteride Treatment in Korean Men with Benign Prostatic Hypertrophy
por: Park, Sung Woon, et al.
Publicado: (2010)

Age-Specific Cutoff Value for the Application of Percent Free Prostate-Specific Antigen (PSA) in Chinese Men with Serum PSA Levels of 4.0–10.0 ng/ml
por: Chen, Rui, et al.
Publicado: (2015)

LncRNA HULC mediates radioresistance via autophagy in prostate cancer cells
por: Chen, Changxuan, et al.
Publicado: (2018)

Metabolomics Profiling Discriminates Prostate Cancer From Benign Prostatic Hyperplasia Within the Prostate-Specific Antigen Gray Zone
por: Xu, Bei, et al.
Publicado: (2021)

Zonal adjusted PSA density improves prostate cancer detection rates compared with PSA in Taiwanese males with PSA < 20 ng/ml
por: Chang, Tsung-Hsin, et al.
Publicado: (2020)

Antigenic determinants of prostate-specific antigen (PSA) and development of assays specific for different forms of PSA.
por: Nilsson, O., et al.
Publicado: (1997)

Nadir PSA level and time to nadir PSA are prognostic factors in patients with metastatic prostate cancer
por: Tomioka, Atsushi, et al.
Publicado: (2014)

Time to PSA rise differentiates the PSA bounce after HDR and LDR brachytherapy of prostate cancer
por: Burchardt, Wojciech, et al.
Publicado: (2018)

Allogeneic Expanded Human Peripheral NK Cells Control Prostate Cancer Growth in a Preclinical Mouse Model of Castration-Resistant Prostate Cancer
por: Wang, Fangming, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_g869djsifgn4mu1n48jle3uchm